The APHINITY Trial

(5:51)

The APHINITY Trial in Early-Stage HER2+ Breast Cancer

(3:30)

APHINITY Trial for HER2+ Breast Cancer

(6:1econd)

APHINITY Trial: Adjuvant Pertuzumab and Trastuzumab

(4:29)

The APHINITY Trial Regimen Efficacy \u0026 Toxicity Profile

(6:28)

Dr. Gorantla Addresses Unanswered Questions From the APHINITY Trial

(1:34)

APHINITY Trial in HER2+ Breast Cancer

(7:30)

APHINITY study

(1:48)

APHINITY Trial: Adjuvant HER2-Targeted Therapy in HER2+ BC

(5:56)

SABCS 2023 HER2+ Breast Cancer Highlights – APHINITY Sub-analysis, KATHERINE update, HER2CLIMB-02

(14:35)

Dr. Crew on the APHINITY Trial Results in HER2+ Breast Cancer

(1:39)

Results of the APHINITY Trial in HER2-Positive Breast Cancer

(2:31)

Dr. von Minckwitz on Phase III Results of the APHINITY Trial for Breast Cancer

(1:30)

Dr. Han on the APHINITY Trial in HER2+ Early-Stage Breast Cancer

(1:40)

Dr. Gorantla on the Impact of the APHINITY Trial in HER2+ Breast Cancer

(2:8)

Results of the Phase III APHINITY Trial in HER2-Positive Breast Cancer

(1:31)

Dr. von Minckwitz on the Safety Profile of the APHINITY Trial for HER2+ Breast Cancer

(1:7)

Dr. Yardley on the APHINITY Trial for HER2-Positive Breast Cancer

(2:27)

Cardiac safety in the APHINITY study

(7:32)